Cite
HARVARD Citation
Zhu, H. et al. (2019). Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma. Medicine. 98 (10), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Zhu, H. et al. (2019). Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma. Medicine. 98 (10), p. . [Online].